Objectives: To update the knowledge of the epidemiology of fungaemia episodes in Spain, the species implicated and their in vitro antifungal susceptibilities.
Introduction
Fungaemia is an important cause of morbidity and mortality closely associated with high healthcare costs in hospitalized patients. Although Candida albicans is still the leading cause of fungaemia worldwide, there are important geographical differences in species distribution and patterns of in vitro susceptibilities to antifungal agents. 1, 2 Thus, performing epidemiological surveillance studies is important to evaluate potential changes in species distribution and antimicrobial susceptibility, and also to assess the potential impact of new antifungal agents on therapy. In the present study, the main epidemiological characteristics of 1357 fungaemia episodes and the in vitro profiles of the susceptibility of isolates to nine antifungal agents are described. Furthermore, we have evaluated the influence of the new species-specific clinical breakpoints (SSCBPs) on resistance rates. To our knowledge, this is the first study reporting the incidence for the newly defined species Candida metapsilosis, Candida orthopsilosis, Candida nivariensis and Candida bracarensis.
Patients and methods

Study design
The FUNGEMYCA survey was a prospective, sequential study carried out over a 13 month period, from 1 January 2009 to 31 January 2010, in 44 Spanish tertiary institutions. The distribution of participant hospitals according to the number of beds was .1000 beds (41%), between 600 and 1000 beds (31.8%) and ,600 (27.2%). All participating hospitals collected and identified the isolates from blood cultures and completed demographic and clinical questionnaires.
Definitions
A fungaemia episode was defined as the isolation of fungi from blood cultures in a patient with temporally related clinical signs and symptoms. Outpatient-acquired fungaemia was considered when the fungal aetiological agent was isolated in blood in the first 48 h after hospital admission. Age groups were neonates (,30 days of age), children (1 month-15 years old), adults (16 -64 years old) and the elderly (.64 years old).
Identification and antifungal susceptibility study
All isolates were identified and their susceptibility to antifungal agents tested at the participating institutions and stored as suspensions in sterile water at room temperature. Antifungal susceptibility testing to nine agents was performed by the microdilution colorimetric Sensititre YeastOne w SYO-09 panel (TREK Diagnostic Systems, Cleveland, OH, USA). On the basis of the good correlation between SensititreYeastOne w and CLSI results, 3 CLSI clinical breakpoints and the recently published SSCBPs and epidemiological cut-off values (ECVs) were applied.
4 -9 For posaconazole and amphotericin B, isolates inhibited by .1 mg/L were considered resistant. Quality controls were performed in each centre using Candida parapsilosis ATCC 22019 and Candida krusei ATCC 6258.
Molecular identification of the C. parapsilosis complex
The identities of C. parapsilosis sensu stricto, C. orthopsilosis and C. metapsilosis isolates were confirmed in a reference laboratory as described by Miranda-Zapico et al. 10 Furthermore, the identities of these species were confirmed by DNA amplifying and further sequencing of ITS1 and ITS4 regions of rRNA genes.
Molecular identification of the Candida glabrata complex
The molecular re-identification of all C. glabrata sensu lato isolates into the species C. glabrata sensu stricto, C. nivariensis and C. bracarensis was performed in a reference laboratory as previously described by Alcoba-Fló rez et al.
11
Statistical analyses
Incidences for each participating centre were calculated as the number of fungaemia episodes per 1000 admissions. Data were analysed with SPSS 10.0.7 for statistics (SPSS Inc., Chicago, IL, USA). Continuous variables were compared with Student's t-test and categorical variables with the x 2 or Fisher's exact test. Comparison of antifungal susceptibility was carried out with log 2 MIC. Differences in antifungal susceptibility patterns among species and age groups were evaluated using non-parametric Kruskal-Wallis analysis of variance followed by a Mann-Whitney U-test with Bonferroni correction for multiples comparison. A P value ,0.05 was considered significant.
Results and discussion
Fungaemia incidence varies depending on hospital characteristics, geographical area and denominator used, which makes comparisons among studies difficult. However, an increase in incidence is being observed worldwide. In our study, the overall incidence (0.92 episodes/1000 admissions, range 0.18 -2.2) is similar to recent studies in Europe (0.41 -1.09 episodes/1000 admissions), 12 but lower than that observed in Brazil (2.49 episodes/ 1000 admissions).
13 Table 1 shows the incidence of episodes caused by the six most common species. Of the total of 1357 episodes of fungaemia reported in the current survey, of note is that C. orthopsilosis was the fifth most common cause of fungaemia (0.020). More fungaemia occurred amongst patients hospitalized in general wards (65.2%) than in those from intensive care units (ICUs) and among elderly patients (46.4%). The main yeasts isolated were C. albicans (44.66%), C. parapsilosis (26.58%), C. glabrata (11.47%), Candida tropicalis (8.21%), C. orthopsilosis (2.18%), C. krusei (1.96%), Candida lusitaniae (0.94%), Cryptococcus neoformans (0.73%), Candida guilliermondii (0.65%), Candida famata (0.44%), Trichosporon asahii (0.36%), Candida dubliniensis (0.29%), C. metapsilosis (0.29%), Rhodotorula glutinis (0.29%), Rhodotorula mucilaginosa (0.22%), Candida kefyr (0.15%), Candida pseudotropicalis (0.07%), Blastoschizomyces capitatus (0.07%), Saccharomyces cerevisiae (0.07%), Trichosporon mucoides (0.07%) and Debaryomyces etchellsii (Pichia etchellsii) (0.07%). Neither C. nivariensis nor C. bracarensis was isolated. In agreement with Pfaller et al.
14 and our previous national survey, 15 the global rank order of species isolated in ICU and non-ICU settings was the same. Of note, C. glabrata was the third most common species in Spain, prevailing over C. tropicalis. The rank order of species in the ICU was characteristic of each institution, possibly being related to the different antifungal practices (prophylaxis and/or treatment) and to the patient management in each of these settings.
Recently C. metapsilosis and C. orthopsilosis have been described as causes of candidaemia in Spain, 10 but the incidence of these species is not well known. Notably, in our survey, C. orthopsilosis was the fifth most common cause of candidaemia, with 0.020 episodes per 1000 admissions being caused by this species. C. metapsilosis fungaemia was anecdotal: four isolates (0.3%, 0.003 episodes per 1000 admissions). However, the incidence of fungaemia by C. parapsilosis was 11 and 74 times higher than that by C. orthopsilosis and C. metapsilosis, respectively.
Mixed fungaemia has been a matter of concern for its potentially poorer prognosis. However, in our study mixed fungaemia was uncommon, as only 20 episodes (1.5%) were caused by two or more fungal species and were reported mainly in ICU settings (50%), confirming the report of Jensen et al. 16 for a single Pemá n et al. 
Continued
Pemá n et al. Fungaemia aetiology varied according to age, gender, hospitalization ward or underlying conditions of the patients. C. albicans was the most prevalent species in neonates (53.6%), adults (44.8%) and elderly patients (47.3%), while C. parapsilosis was predominant in children (48.9%), with statistically significant differences between both species (P,0.05). Table 2 summarizes the results of in vitro susceptibility, applying both current and new CLSI SSCBPs. Overall, 88.9% of yeast isolates were susceptible to the nine antifungal agents tested. Although there has been wide use of fluconazole in the last decade in Spain, the susceptibility rate to this agent continues to be very high (91.9%). These findings have also been reported by other authors.
14 More than 95% of C. glabrata and C. krusei isolates were highly susceptible to anidulafungin, micafungin and voriconazole. Conversely, itraconazole was the least active drug, 5.4% of yeast isolates being resistant and 77.6% susceptible. Important resistance rates were only observed in C. glabrata for itraconazole (24.1%) and posaconazole (14.5%), and in C. krusei for itraconazole (81.5%).
Resistance rates changed moderately when applying the new SSCBPs, and the most remarkable increases were observed in C. parapsilosis for fluconazole (from 0% to 4.1%), and in C. krusei for voriconazole (from 0% to 3.7%). Echinocandin resistance increased between 0 and 4.1 times depending on the fungal species and the specific drug, C. glabrata being the most affected species.
For the four most common species, the percentage of isolates above the posaconazole ECV ranged from 0.8% for C. parapsilosis to 49.6% for C. tropicalis. While the percentage of isolates inhibited by .1 mg/L posaconazole ranged from 0.3% for C. parapsilosis to 14.5% for C. glabrata, this latter species was the only one where the percentage of non-wild-type isolates diminished with the application of the ECV.
Amphotericin B and flucytosine were the agents with the lowest overall resistance rates (0.2% and 0.5%, respectively). Thus the overall resistance rates to antifungal agents in our study were very low, being even lower in ICU settings.
Excluding those intrinsically resistant species, echinocandins show a broad antifungal activity. Moreover, resistance rates (≤1.1%) varied slightly when applying the revised SSCBPs for most species. However, increased resistance rates were observed in C. glabrata (from 1.9% to 3.2%) and C. krusei (from 3.7% to 7.4%), rates similar to those reported by other authors. 14 In summary, we present the largest multicentre fungaemia study conducted in Spain and provide the incidence of the cryptic species included in the C. parapsilosis and C. glabrata complexes and the in vitro susceptibility of blood isolates to nine of the currently most used systemic antifungal agents. Furthermore, we have determined the repercussions of the recent ECVs and SSCBPs on resistance rates. The large size of this study minimizes its clinical limitations, thus providing valuable information for clinicians before establishing empirical treatment in patients with fungaemia.
